Methods of treating cardiovascular-related disease

A method of reducing triglycerides in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an ALK2 antibody or an ALK2 binding fragment thereof, comprising:

• (a) a light chain complementarity determining region (CDR) 1 comprising the amino acid sequence SGSSSNIGSNYVS (SEQ ID NO:
• 1);
• a light chain CDR2 comprising the amino acid sequence VLIYKNNHRPS (SEQ ID NO:
• 24);
• a light chain CDR3 comprising the amino acid sequence ASWDHSDRFYV (SEQ ID NO:
• 4);
• a heavy chain CDR1 comprising the amino acid sequence GGTFSSYGVS (SEQ ID NO:
• 31;
• a heavy chain CDR2 comprising the amino acid sequence WMGGIIPHFGIANYAQKFQG (SEQ ID NO:
• 36;
• and a heavy chain CDR3 comprising the amino acid sequence EIGSLDI (SEQ ID NO:
• 13);
• (b) a light chain CDR1 comprising the amino acid sequence SGDSIPSFFAS (SEQ ID NO:
• 18);
• a light chain CDR2 comprising the amino acid sequence LVIYRDSNRPS (SEQ ID NO:
• 25);
• a light chain CDR3 comprising the amino acid sequence YVTAPWKSIW (SEQ ID NO:
• 5);
• a heavy chain CDR1 comprising the amino acid sequence GFTFSSHAMS (SEQ ID NO:
• 32);
• a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKADSGTTDYAAPVKG (SEQ ID NO:
• 37);
• and a heavy chain CDR3 comprising the amino acid sequence DYGVAFAY (SEQ ID NO:
• 14);
• (c) a light chain CDR1 comprising the amino acid sequence SGDNIGTKYAY (SEQ ID NO:
• 19);
• a light chain CDR2 comprising the amino acid sequence LVIYGDSDRPS (SEQ ID NO:
• 26);
• a light chain CDR3 comprising the amino acid sequence YSADAQQMKA (SEQ ID NO:
• 6);
• a heavy chain CDR1 comprising the amino acid sequence GFTFNSSAMS (SEQ ID NO:
• 33);
• a heavy chain CDR2 comprising the amino acid sequence WVGRIKSKRDGYTTDYAAPVKG (SEQ ID NO:
• 38);
• and a heavy chain CDR3 comprising the amino acid sequence DYGGLKFDY (SEQ ID NO:
• 15);
• (d) a light chain CDR1 comprising the amino acid sequence SGDNLRKYSAH (SEQ ID NO:
• 20);
• a light chain CDR2 comprising the amino acid sequence LVIYYDNKRPS (SEQ ID NO:
• 27);
• a light chain CDR3 comprising the amino acid sequence QVYASVHRM (SEQ ID NO:
• 7);
• a heavy chain CDR1 comprising the amino acid sequence GGTFSSYAIH (SEQ ID NO:
• 34);
• a heavy chain CDR2 comprising the amino acid sequence WMGRIIPDFGTANYAQKFQG (SEQ ID NO:
• 39);
• and a heavy chain CDR3 comprising the amino acid sequence GPTQAIHYFAY (SEQ ID NO:
• 16);
• or
• (e) a light chain CDR1 comprising the amino acid sequence SGDSLGSKSVH (SEQ ID NO:
• 21);
• a light chain CDR2 comprising the amino acid sequence LVIYRDSKRPS (SEQ ID NO:
• 28);
• a light chain CDR3 comprising the amino acid sequence QTYDWSHFGW (SEQ ID NO:
• 8);
• a heavy chain CDR1 comprising the amino acid sequence GFTFSSAAMH (SEQ ID NO:
• 35);
• a heavy chain CDR2 comprising the amino acid sequence WVSVISSDGGSTYYADSVKG (SEQ ID NO:
• 12);
• and a heavy chain CDR3 comprising the amino acid sequence AGFILGSLGVAWMDV (SEQ ID NO:
• 17).